Virginia Litwin

Virginia Litwin


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2023 in Current Protocols
Verified
Journal Article
Closed access
NSNithianandan Selliah
Nithianandan Selliah
VNVeronica Nash
Veronica Nash
SESteven Eck
Steven Eck
CGCherie Green
Cherie Green
TOTeri Oldaker
Teri Oldaker
VLVirginia Litwin
Virginia Litwin

1 February 2022 in AAPS Open
Verified
Journal Article
Open access
PDF file
JMJoel Mathews
Joel Mathews
LALakshmi Amaravadi
Lakshmi Amaravadi
SESteven Eck
Steven Eck
LSLauren Stevenson
Lauren Stevenson
YWYow-Ming C. Wang
Yow-Ming C. Wang
VLVirginia Litwin
Virginia Litwin
This conference report summarized a full-day workshop, “best practices for the development and fit-for-purpose validation of biomarker methods,” which was held prior to the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 Congress, San Antonio, TX, November 2019. The purpose of the workshop was to bring together thought leaders in biomarker assay development in order to identify which assay parameters and key statistical measures need to be considered when developing a biomarker assay. A diverse group of more than 40 scientists participated in the workshop. The workshop and subsequent working dinner stimulated robust discussion. While a consensus on best practices was not achieved, some common themes and major points to consider for biomarker assay development have been identified and agreed on. The focus of this conference report is to summarize the presentations and discussions which occurred at the workshop. Biomarker assay validation is a complex and an evolving area with discussions ongoing.

16 September 2021 in Bioanalysis
Verified
Journal Article
Closed access
CGChristèle Gonneau
Christèle Gonneau
LWLili Wang
Lili Wang
SMShibani Mitra-Kaushik
Shibani Mitra-Kaushik
PTPaul C Trampont
Paul C Trampont
VLVirginia Litwin
Virginia Litwin

Verified
Journal Article
Open access
PDF file
TBThomas C Beadnell
Thomas C Beadnell
SJSusmita Jasti
Susmita Jasti
RWRuqi Wang
Ruqi Wang
BDBruce Hewat Davis
Bruce Hewat Davis
VLVirginia Litwin
Virginia Litwin
Monitoring chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is a specialized application of flow cytometry. Unlike the CAR T-cell monitoring for individual patients conducted in clinical laboratories, the data generated during a clinical trial will be used not only to monitor the therapeutic response of a single patient, but determine the success of the therapy itself, or even of an entire class of therapeutic compounds. The data, typically acquired at multiple testing laboratories, will be compiled into a single database. The data may also be used for mathematical modeling of cellular kinetics or to identify predictive biomarkers. With the expanded context of use, a robust, standardized assay is mandatory in order to generate a valuable and reliable data set. Hence, the requirements for assay validation, traceable calibration, technology transfer, cross-instrument standardization and regulatory compliance are high.

30 December 2025 in Cytometry Part A
Verified
Journal Article
Closed access
PWPaul K. Wallace
Paul K. Wallace
EJEvan R Jellison
Evan R Jellison
STSherry Thornton
Sherry Thornton
KKKathleen Kluepfel
Kathleen Kluepfel
JBJessica Back
Jessica Back
Bartek RajwaBartek Rajwa
Bartek Rajwa

19 April 2017
Verified
Book Chapter
Closed access
PDF file
VLVirginia Litwin
Virginia Litwin
CGCherie Green
Cherie Green
AVAlessandra Vitaliti
Alessandra Vitaliti